Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNFR2 agonism for ex vivo expansion of regulatory T cells from patients with autoimmune or inflammatory disease
NL-OMON50055Recruiting
- Sponsor
- Maastricht University
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of MR2-1 in systemic lupus erythematosus (SLE), anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), multiple sclerosis (MS) and 1 more (5 cohorts), sponsored by Maastricht University. Primary endpoints: In vitro proliferation of expanded regulatory T cells, Suppressive capacity of expanded regulatory T cells and 1 more. Started Feb 2019; status: recruiting.
02
Drugs
MR2-1
03
Conditions
systemic lupus erythematosus (SLE)anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)multiple sclerosis (MS)Crohn's disease
Beyond the preview
Go deeper on NL-OMON50055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50055.